NeuroOne to Host Investor Webinar Following Recent FDA Clearance

NeuroOne Medical Technologies Corporation will hold a virtual roadshow webinar on October 7, 2025, at 8:30 a.m. Eastern Standard Time to discuss its business operations, recent FDA clearance and corporate updates. The medical technology company, focused on improving surgical care options for patients suffering from neurological disorders, will provide investors with comprehensive insights into its current position and future direction.

The webinar represents a significant opportunity for stakeholders to understand the implications of the company's recent FDA clearance and how it positions NeuroOne in the competitive medical technology landscape. Investors can access the webcast through the NMTC Virtual Webinar Link or by dialing 888-506-0062 within the United States or 973-528-0011 internationally using access code 619723. The event will include a presentation followed by a question-and-answer session, allowing direct engagement with company leadership.

This investor communication comes at a crucial time as NeuroOne continues developing and commercializing minimally invasive solutions for EEG recording, monitoring, ablation, drug delivery and stimulation for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors and chronic pain due to failed back surgeries. The company's focus on improving patient outcomes while reducing procedural costs makes this webinar particularly important for understanding its market strategy and technological advancements.

The availability of a playback option through October 21, 2025, ensures that investors who cannot attend live can still access this critical information. Participants can listen to the recording by calling 877-481-4010 within the United States or 919-882-2331 internationally using replay passcode 53045. This extended accessibility underscores the company's commitment to transparent communication with its investor community during a period of significant regulatory and commercial developments.